Eagle Pharmaceuticals Appoints Experienced CFO Christopher Krawtschuk For Financial Leadership

Eagle Pharmaceuticals, Inc. today announced that Christopher Krawtschuk has been appointed as the company’s Chief Financial Officer (CFO), effective November 11, 2024. Following Krawtschuk’s appointment, Steven Ratoff will step down as interim CFO but will continue serving as a director on Eagle’s board of directors.

Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals, said in a statement, “Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team. His experience guiding companies through transitional periods brings a valuable perspective to Eagle.”

Krawtschuk previously held roles as CFO and Treasurer at Bluebird Bio, where he provided strategic financial oversight. Before that, he was CFO at Jubilant Pharma, focusing on capital strategy and optimisation. At Morphosys, a German-based company, Krawtschuk served as U.S. CFO and Treasurer, building a U.S. commercial presence in oncology. 

Earlier in his career, he was the lead divisional controller at Pfizer, supporting strategy, operations, and business development initiatives. Krawtschuk began his financial career with PricewaterhouseCoopers, progressing through roles of increasing responsibility between 2001 and 2016. He earned a B.S. in Accounting from William Paterson University and holds a CPA license.

Christopher Krawtschuk expressed, “Joining Eagle Pharmaceuticals at this time represents a unique opportunity to contribute to the Company. I look forward to working with Michael and his talented colleagues as we strive to execute our operational priorities.”